glp 1 receptor agonist drugs GLP-1 Agonists: An Alternative for Rapid-Acting Insulin? Chemical structures of GLP-1 receptor

Description

H., Huang, C

Currently available treatment with proven outcomes Semaglutide FDA-approved for diabetes (Ozempic), obesity (Wegovy), and CV risk reduction with 7+ years of clinical and post-marketing data Cardiovascular risk reduction Semaglutide SELECT trial demonstrated 20% MACE reduction in 17,604 patients -- the first anti-obesity drug with proven cardiovascular benefit Maximum weight loss potential Retatrutide Phase 2 data showed 24.2% weight loss at 48 weeks with weight curves still declining, though Phase 3 confirmation is required Metabolic liver disease (MASLD/MASH) Retatrutide Glucagon receptor agonism directly promotes hepatic fat oxidation, a mechanistic advantage for liver-specific outcomes Oral administration preference Semaglutide Only incretin-class drug available as an oral tablet (Rybelsus), with higher-dose oral formulations under development Type 2 diabetes with established treatment guidelines Semaglutide Integrated into clinical guidelines with multiple approved doses and formulations, extensive comparative data, and guideline positioning Continue Your Research Get comparison updates We publish new head-to-head comparisons regularly

For example, the FDAs approval of Lillys ZepBound (tirzepatide for chronic weight management) in late 2023 was based on phase III data showing superior weight loss compared to placebo

Mechanisms Behind GLP-1 Induced Weight Loss

Risks of diabetic foot syndrome and amputation associated with sodium glucose co-transporter 2 inhibitors: a meta-analysis of randomized controlled trials